Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

Completed · Phase 1

Conditions studied: Postmenopausal Symptoms

In brief

The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and multiple doses.

Key facts

Study ID
NCT01829919
Run by
Noven Therapeutics
People needed
24
Starts
2011-07-01
Expected to finish
2011-08-01
Last updated by the study team
2015-10-15

Who can join

Age: 40 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.